HS-10365

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

NSCLC (advanced Non-small Cell Lung Cancer)Solid Tumor

Phase 1

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Solid Tumor

Start: 2021-11-09End: 2025-12-31Target: 306Updated: 2023-06-01

Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function

Not yet recruitingNCT06823258

Jiangsu Hansoh Pharmaceutical Co., Ltd.NSCLC (advanced Non-small Cell Lung Cancer)

Start: 2025-02-28End: 2025-07-31Target: 32Updated: 2025-02-12

Related Papers

Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients

Cancer Research2023-04-147 citations